Merck has unexpectedly discontinued Recarbrio, an antibiotic that the U.S. Food and Drug Administration once pegged as a treatment of last resort for serious infections. According to STAT, the drugmaker stopped supplying the three-drug combination injection earlier this month without explaining its decision. The drug was approved seven years ago for adults and children with limited or no alternative options, covering hospital- or ventilator-associated pneumonia, complicated urinary tract infections, and complicated stomach infections.
The FDA's original designation as a last-resort therapy was intended to mitigate antibiotic resistance, but it also constrained the drug's market potential. Merck did not disclose Recarbrio sales in its regulatory filings, and the company's silence on the rationale leaves observers to infer that commercial considerations played a role.
This discontinuation highlights a broader tension: while antibiotics are crucial for public health, their careful use to preserve effectiveness limits revenue, making them less attractive to large pharmaceutical companies. STAT notes that the move underscores concerns about the commitment big drugmakers are willing to make to this field, even as superbug resistance remains a growing threat. The report offers no other sources or alternative explanations, so the full picture of Merck's decision remains unclear.